Developing a globally competitive life sciences industry
Singapore's policies should be further refined and tailored towards enterprises that will be competitive in major markets.
IN the field of life sciences, Singapore has now gained an outsized standing in the global scientific community despite the country's relatively small size. However, this standing has yet to translate into expected downstream value-capture for the economy, especially in the startup/SME segment. This is in spite of the budding emergence of promising homegrown life science companies with a few success stories and a healthy number of out-licences of Singapore-owned IP.
With the rise of China, Singapore's role as an unrivalled Asian hub is changing rapidly. Many multinationals will choose to locate their Asian headquarters in one of the Chinese metropolises. While Singapore can continue to count on being the economic capital of South-east Asia, developing a homegrown ecosystem of life science SMEs/startups, some of which can eventually become competitive players on the global stage, should feature on the national agenda.
The life sciences industry is highly globalised, evergreen and knowledge-intensive and impacts humanity on a broad scale. Though consolidation is occurring within some segments of the industry, many opportunities for disruption still exist, allowing startups and SMEs to thrive, especially those that aim to address unmet needs.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Columns
‘Competition for talent’ a poor excuse to keep key executives’ pay under wraps
OCBC should put its properties into a Reit and distribute the trust’s units to shareholders
Why a stronger US dollar is dangerous
An overstimulated US economy is asking for trouble
Too many property agents? Cap commissions on home sales
Time to study broadening of private market access